1
|
Wang H, Lin S, Feng L, Huang B, Lu X, Yang Z, Jiang Z, Li Y, Zhang X, Wang M, Wang B, Kong L, Pan Q, Bai S, Li Y, Yang Y, Lee WYW, Currie PD, Lin C, Jiang Y, Chen J, Tortorella MD, Li H, Li G. Low-Dose Staphylococcal Enterotoxin C2 Mutant Maintains Bone Homeostasis via Regulating Crosstalk between Bone Formation and Host T-Cell Effector Immunity. Adv Sci (Weinh) 2023; 10:e2300989. [PMID: 37552005 PMCID: PMC10558680 DOI: 10.1002/advs.202300989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/13/2023] [Revised: 06/22/2023] [Indexed: 08/09/2023]
Abstract
Studies in recent years have highlighted an elaborate crosstalk between T cells and bone cells, suggesting that T cells may be alternative therapeutic targets for the maintenance of bone homeostasis. Here, it is reported that systemic administration of low-dose staphylococcal enterotoxin C2 (SEC2) 2M-118, a form of mutant superantigen, dramatically alleviates ovariectomy (OVX)-induced bone loss via modulating T cells. Specially, SEC2 2M-118 treatment increases trabecular bone mass significantly via promoting bone formation in OVX mice. These beneficial effects are largely diminished in T-cell-deficient nude mice and can be rescued by T-cell reconstruction. Neutralizing assays determine interferon gamma (IFN-γ) as the key factor that mediates the beneficial effects of SEC2 2M-118 on bone. Mechanistic studies demonstrate that IFN-γ stimulates Janus kinase/signal transducer and activator of transcription (JAK-STAT) signaling, leading to enhanced production of nitric oxide, which further activates p38 mitogen-activated protein kinase (MAPK) and Runt-related transcription factor 2 (Runx2) signaling and promotes osteogenic differentiation. IFN-γ also directly inhibits osteoclast differentiation, but this effect is counteracted by proabsorptive factors tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β) secreted from IFN-γ-stimulated macrophages. Taken together, this work provides clues for developing innovative approaches which target T cells for the prevention and treatment of osteoporosis.
Collapse
Affiliation(s)
- Haixing Wang
- Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Li Ka Shing Institute of Health SciencesThe Chinese University of Hong KongHong Kong999077China
- Centre for Regenerative Medicine and HealthHong Kong Institute of Science & InnovationChinese Academy of SciencesHong Kong999077China
| | - Sien Lin
- Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Li Ka Shing Institute of Health SciencesThe Chinese University of Hong KongHong Kong999077China
| | - Lu Feng
- Centre for Regenerative Medicine and HealthHong Kong Institute of Science & InnovationChinese Academy of SciencesHong Kong999077China
| | - Baozhen Huang
- Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Li Ka Shing Institute of Health SciencesThe Chinese University of Hong KongHong Kong999077China
| | - Xuan Lu
- Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Li Ka Shing Institute of Health SciencesThe Chinese University of Hong KongHong Kong999077China
| | - Zhengmeng Yang
- Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Li Ka Shing Institute of Health SciencesThe Chinese University of Hong KongHong Kong999077China
| | - Zhaowei Jiang
- Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Li Ka Shing Institute of Health SciencesThe Chinese University of Hong KongHong Kong999077China
| | - Yu‐Cong Li
- Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Li Ka Shing Institute of Health SciencesThe Chinese University of Hong KongHong Kong999077China
| | - Xiaoting Zhang
- Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Li Ka Shing Institute of Health SciencesThe Chinese University of Hong KongHong Kong999077China
| | - Ming Wang
- Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Li Ka Shing Institute of Health SciencesThe Chinese University of Hong KongHong Kong999077China
| | - Bin Wang
- Greater Bay Area Institute of Precision Medicine (Guangzhou)Fudan University2nd Nanjiang Rd, Nansha DistrictGuangzhou511458China
| | - Lingchi Kong
- Department of Orthopaedic SurgeryShanghai Jiao Tong University Affiliated Sixth People's HospitalYishan Rd. 600Shanghai200233China
| | - Qi Pan
- Department of OrthopaedicsSouth China HospitalShenzhen UniversityShenzhen518116China
| | - Shanshan Bai
- Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Li Ka Shing Institute of Health SciencesThe Chinese University of Hong KongHong Kong999077China
| | - Yuan Li
- Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Li Ka Shing Institute of Health SciencesThe Chinese University of Hong KongHong Kong999077China
| | - Yongkang Yang
- Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Li Ka Shing Institute of Health SciencesThe Chinese University of Hong KongHong Kong999077China
| | - Wayne Yuk Wai Lee
- Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Li Ka Shing Institute of Health SciencesThe Chinese University of Hong KongHong Kong999077China
| | - Peter D. Currie
- Australian Regenerative Medicine InstituteMonash UniversityWellington RoadClaytonVictoria3800Australia
| | - Changshuang Lin
- Shenyang Xiehe Biopharmaceutical Co. Ltd.ShenyangLiaoning Province110179China
| | - Yanfu Jiang
- Shenyang Xiehe Biopharmaceutical Co. Ltd.ShenyangLiaoning Province110179China
| | - Juyu Chen
- Shenyang Xiehe Biopharmaceutical Co. Ltd.ShenyangLiaoning Province110179China
| | - Micky D. Tortorella
- Centre for Regenerative Medicine and HealthHong Kong Institute of Science & InnovationChinese Academy of SciencesHong Kong999077China
| | - Hongyi Li
- Shenyang Xiehe Biopharmaceutical Co. Ltd.ShenyangLiaoning Province110179China
| | - Gang Li
- Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Li Ka Shing Institute of Health SciencesThe Chinese University of Hong KongHong Kong999077China
| |
Collapse
|
2
|
Fu X, Xu M, Yu Z, Gu W, Zhang Z, Zhang B, Wang X, Su Z, Zhang C. Staphylococcal Enterotoxin C2 Mutant-Induced Antitumor Immune Response Is Controlled by CDC42/MLC2-Mediated Tumor Cell Stiffness. Int J Mol Sci 2023; 24:11796. [PMID: 37511553 PMCID: PMC10380429 DOI: 10.3390/ijms241411796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Revised: 07/03/2023] [Accepted: 07/20/2023] [Indexed: 07/30/2023] Open
Abstract
As a biological macromolecule, the superantigen staphylococcal enterotoxin C2 (SEC2) is one of the most potent known T-cell activators, and it induces massive cytotoxic granule production. With this property, SEC2 and its mutants are widely regarded as immunomodulating agents for cancer therapy. In a previous study, we constructed an MHC-II-independent mutant of SEC2, named ST-4, which exhibits enhanced immunocyte stimulation and antitumor activity. However, tumor cells have different degrees of sensitivity to SEC2/ST-4. The mechanisms of immune resistance to SEs in cancer cells have not been investigated. Herein, we show that ST-4 could activate more powerful human lymphocyte granule-based cytotoxicity than SEC2. The results of RNA-seq and atomic force microscopy (AFM) analysis showed that, compared with SKOV3 cells, the softer ES-2 cells could escape from SEC2/ST-4-induced cytotoxic T-cell-mediated apoptosis by regulating cell softness through the CDC42/MLC2 pathway. Conversely, after enhancing the stiffness of cancer cells by a nonmuscle myosin-II-specific inhibitor, SEC2/ST-4 exhibited a significant antitumor effect against ES-2 cells by promoting perforin-dependent apoptosis and the S-phase arrest. Taken together, these data suggest that cell stiffness could be a key factor of resistance to SEs in ovarian cancer, and our findings may provide new insight for SE-based tumor immunotherapy.
Collapse
Affiliation(s)
- Xuanhe Fu
- Institute of Applied Ecology, Chinese Academy of Sciences, No. 72 Wenhua Road, Shenyang 110016, China
- Department of Immunology, Shenyang Medical College, No. 146 Huanghe North Street, Shenyang 110034, China
- Key Laboratory of Superantigen Research of Liao Ning Province, Shenyang 110016, China
| | - Mingkai Xu
- Institute of Applied Ecology, Chinese Academy of Sciences, No. 72 Wenhua Road, Shenyang 110016, China
- Key Laboratory of Superantigen Research of Liao Ning Province, Shenyang 110016, China
| | - Zhixiong Yu
- Department of Immunology, Shenyang Medical College, No. 146 Huanghe North Street, Shenyang 110034, China
| | - Wu Gu
- Institute of Applied Ecology, Chinese Academy of Sciences, No. 72 Wenhua Road, Shenyang 110016, China
- University of Chinese Academy of Sciences, Beijing 100049, China
| | - Zhichun Zhang
- Institute of Applied Ecology, Chinese Academy of Sciences, No. 72 Wenhua Road, Shenyang 110016, China
- University of Chinese Academy of Sciences, Beijing 100049, China
| | - Bowen Zhang
- Institute of Applied Ecology, Chinese Academy of Sciences, No. 72 Wenhua Road, Shenyang 110016, China
- University of Chinese Academy of Sciences, Beijing 100049, China
| | - Xiujuan Wang
- Institute of Applied Ecology, Chinese Academy of Sciences, No. 72 Wenhua Road, Shenyang 110016, China
- Key Laboratory of Superantigen Research of Liao Ning Province, Shenyang 110016, China
| | - Zhencheng Su
- Institute of Applied Ecology, Chinese Academy of Sciences, No. 72 Wenhua Road, Shenyang 110016, China
- Key Laboratory of Superantigen Research of Liao Ning Province, Shenyang 110016, China
| | - Chenggang Zhang
- Institute of Applied Ecology, Chinese Academy of Sciences, No. 72 Wenhua Road, Shenyang 110016, China
- Key Laboratory of Superantigen Research of Liao Ning Province, Shenyang 110016, China
| |
Collapse
|
3
|
Zhao WB, Shen Y, Liu WH, Li YM, Jin SJ, Xu YC, Pan LQ, Zhou Z, Chen SQ. Soluble Expression of Fc-Fused T Cell Receptors Allows Yielding Novel Bispecific T Cell Engagers. Biomedicines 2021; 9:790. [PMID: 34356854 PMCID: PMC8301436 DOI: 10.3390/biomedicines9070790] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Revised: 06/24/2021] [Accepted: 07/05/2021] [Indexed: 11/21/2022] Open
Abstract
The specific recognition of T cell receptors (TCR) and peptides presented by human leukocyte antigens (pHLAs) is the core step for T cell triggering to execute anti-tumor activity. However, TCR assembly and soluble expression are challenging, which precludes the broad use of TCR in tumor therapy. Herein, we used heterodimeric Fc to assist in the correct assembly of TCRs to achieve the stable and soluble expression of several TCRs in mammalian cells, and the soluble TCRs enable us to yield novel bispecific T cell engagers (TCR/aCD3) through pairing them with an anti-CD3 antibody. The NY-ESO-1/LAGE-1 targeted TCR/aCD3 (NY-TCR/aCD3) that we generated can redirect naïve T cells to specific lysis antigen-positive tumor cells, but the potency of the NY-TCR/aCD3 was disappointing. Furthermore, we found that the activation of T cells by NY-TCR/aCD3 was mild and unabiding, and the activity of NY-TCR/aCD3 could be significantly improved when we replaced naïve T cells with pre-activated T cells. Therefore, we employed the robust T cell activation ability of staphylococcal enterotoxin C2 (SEC2) to optimize the activity of NY-TCR/aCD3. Moreover, we found that the secretions of SEC2-activated T cells can promote HLA-I expression and thus increase target levels, which may further contribute to improving the activity of NY-TCR/aCD3. Our study described novel strategies for soluble TCR expression, and the optimization of the generation and potency of TCR/aCD3 provided a representative for us to fully exploit TCRs for the precision targeting of cancers.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Zhan Zhou
- Institute of Drug Metabolism and Pharmaceutical Analysis & Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; (W.-B.Z.); (Y.S.); (W.-H.L.); (Y.-M.L.); (S.-J.J.); (Y.-C.X.); (L.-Q.P.)
| | - Shu-Qing Chen
- Institute of Drug Metabolism and Pharmaceutical Analysis & Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; (W.-B.Z.); (Y.S.); (W.-H.L.); (Y.-M.L.); (S.-J.J.); (Y.-C.X.); (L.-Q.P.)
| |
Collapse
|
4
|
Fu X, Xu M, Song Y, Li Y, Zhang H, Zhang J, Zhang C. Enhanced interaction between SEC2 mutant and TCR Vβ induces MHC II-independent activation of T cells via PKCθ/NF-κB and IL-2R/STAT5 signaling pathways. J Biol Chem 2018; 293:19771-19784. [PMID: 30352872 DOI: 10.1074/jbc.ra118.003668] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2018] [Revised: 09/23/2018] [Indexed: 11/06/2022] Open
Abstract
SEC2, a major histocompatibility complex class II (MHC II)-dependent T-cell mitogen, binds MHC II and T-cell receptor (TCR) Vβs to induce effective co-stimulating signals for clonal T-cell expansion. We previously characterized a SEC2 mutant with increased recognition of TCR Vβs, ST-4, which could intensify NF-κB signaling transduction, leading to IL-2 production and T-cell activation. In this study, we found that in contrast to SEC2, ST-4 could induce murine CD4+ T-cell proliferation in a Vβ8.2- and Vβ8.3-specific manner in the absence of MHC II+ antigen-presenting cells (APCs). Furthermore, although IL-2 secretion in response to either SEC2 or ST-4 stimulation was accompanied by up-regulation of protein kinase Cθ (PKCθ), inhibitor of κB (IκB), α and β IκB kinase (IKKα/β), IκBα, and NF-κB in mouse splenocytes, only ST-4 could activate CD4+ T cells in the absence of MHC II+ APCs through the PKCθ/NF-κB signaling pathway. The PKCθ inhibitor AEB071 significantly suppressed SEC2/ST-4-induced T-cell proliferation, CD69 and CD25 expression, and IL-2 secretion with or without MHC II+ APCs. Further, SEC2/ST-4-induced changes in PKCθ/NF-κB signaling were significantly relieved by AEB071 in a dose-dependent manner. Using Lck siRNA, we found that Lck controlled SEC2/ST-4-induced phosphorylation of PKCθ. We also demonstrated that the IL-2R/STAT5 pathway is essential for SEC2/ST-4-induced T-cell activation. Collectively, our data demonstrate that an enhanced ST-4-TCR interaction can compensate for lack of MHC II and stimulate MHC II-free CD4+ T-cell proliferation via PKCθ/NF-κB and IL-2R/STAT5 signaling pathways. Compared with SEC2, intensified PKCθ/NF-κB and IL-2R/STAT5 signals induced by ST-4 lead to enhanced T-cell activation. The results of this study will facilitate better understanding of TCR-based immunotherapies for cancer.
Collapse
Affiliation(s)
- Xuanhe Fu
- From the Institute of Applied Ecology, Chinese Academy of Sciences, 72 WenHua Road, Shenyang 110016, China and.,the School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 WenHua Road, Shenyang 110016, China
| | - Mingkai Xu
- From the Institute of Applied Ecology, Chinese Academy of Sciences, 72 WenHua Road, Shenyang 110016, China and
| | - Yubo Song
- From the Institute of Applied Ecology, Chinese Academy of Sciences, 72 WenHua Road, Shenyang 110016, China and
| | - Yongqiang Li
- From the Institute of Applied Ecology, Chinese Academy of Sciences, 72 WenHua Road, Shenyang 110016, China and
| | - Huiwen Zhang
- From the Institute of Applied Ecology, Chinese Academy of Sciences, 72 WenHua Road, Shenyang 110016, China and
| | - Jinghai Zhang
- the School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, 103 WenHua Road, Shenyang 110016, China
| | - Chenggang Zhang
- From the Institute of Applied Ecology, Chinese Academy of Sciences, 72 WenHua Road, Shenyang 110016, China and
| |
Collapse
|
5
|
Zhao W, Li Y, Liu W, Ding D, Xu Y, Pan L, Chen S. Transcytosis, Antitumor Activity and Toxicity of Staphylococcal Enterotoxin C2 as an Oral Administration Protein Drug. Toxins (Basel) 2016; 8:E185. [PMID: 27322320 DOI: 10.3390/toxins8060185] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2016] [Accepted: 06/06/2016] [Indexed: 11/17/2022] Open
Abstract
Staphylococcal enterotoxin C2 (SEC2) is a classical superantigen (SAg), which can tremendously activate T lymphocytes at very low dosage, thus exerting its powerful antitumor activity. As an intravenous protein drug and a bacterial toxin, SEC2 has some limitations including poor patient compliance and toxic side effects. In this research, we devoted our attention to studying the antitumor activity and toxicity of SEC2 as a potential oral administration protein drug. We proved that His-tagged SEC2 (SEC2-His) could undergo facilitated transcytosis on human colon adenocarcinoma (Caco-2) cells and SEC2-His was detected in the blood of rats after oral administration. Furthermore, oral SEC2-His caused massive cytokine release and immune cell enrichment around tumor tissue, leading to inhibition of tumor growth in vivo. Meanwhile, although SEC2-His was dosed up to 32 mg/kg in mice, no significant toxicity was observed. These data showed that SEC2 can cross the intestinal epithelium in an immunologically integral form, maintaining antitumor activity but with reduced systemic toxicity. Therefore, these results may have implications for developing SEC2 as an oral administration protein drug.
Collapse
|
6
|
Liu Y, Xu M, Li X, Sun J, Zhang C, Zhang H. The construction of a bifunctional fusion protein consisting of SEC2 and EGFP. Biotechnol Appl Biochem 2014; 61:565-71. [PMID: 24397332 DOI: 10.1002/bab.1203] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2013] [Accepted: 12/27/2013] [Indexed: 11/09/2022]
Abstract
The aim of this study was to construct a bifunctional fusion protein consisting of staphylococcal enterotoxin C2 (SEC2) and enhanced green fluorescent protein (EGFP). We inserted EGFP and SEC2 fragments into the pET-28a(+) vector to create the expression plasmid vector, pET-28a(+)-SEC2-EGFP, using a two-step method. After verification of the plasmid, successful isolation of the fusion protein, SEC2-EGFP, was achieved by Ni+-affinity chromatography. Fluorescence microscopy, methylthiazol tetrazolium, and flow cytometry assays demonstrated that the constructed fusion protein not only retained the fluorescence signal of EGFP but also exhibited SEC2 bioactivity. Therefore, SEC2-EGFP is a promising tool for the study of the detailed temporal and spatial distributions of SEC2 in cells. Future studies with this vector may help uncover novel therapeutic strategies to treat or manage SEC2-associated diseases and be a new clinical tool for exploiting SEC2 in immunotherapy.
Collapse
Affiliation(s)
- Yanli Liu
- Institute of Applied Ecology, Chinese Academy of Sciences, Shenyang, People's Republic of China; Department of Life Science and Technology, Xinxiang Medical University, Xinxiang, People's Republic of China
| | | | | | | | | | | |
Collapse
|
7
|
Liu Y, Xu M, Su Z, Cai Y, Zhang G, Zhang H. Increased T-cell stimulating activity by mutated SEC2 correlates with its improved antitumour potency. Lett Appl Microbiol 2012; 55:362-9. [PMID: 22925007 DOI: 10.1111/j.1472-765x.2012.03303.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
AIMS To investigate the improved antitumour activity of SAM-3 compared with recombinant staphylococcal enterotoxins C2 (rSEC2). METHODS AND RESULTS Methylthiazol tetrazolium and flow cytometry assays showed that the antitumour activity of SAM-3 in vivo was improved because of enhanced T-cell stimulating potency, resulting in massive activation of T cells, particularly CD4(+) and CD8(+) T cells, and subsequent cytokine release. Quantitative real-time PCR assay showed that despite similar Vβ specificities induced by rSEC2 and SAM-3, the quantities of activated T cells bearing specific Vβin vitro were different. CONCLUSIONS The results strongly suggested that the increased SAM-3-T-cell receptor (TCR) binding affinity contributed to massive T-cell activation and cytokine release, substantially amplifying antitumour immune response in vivo. SIGNIFICANCE AND IMPACT OF THE STUDY This study provided evidence for the mechanism of SAM-3 antitumour activity improvement compared with rSEC2. Results indicated that SAM-3 could be used as a potent powerful candidate agent for tumour treatment in clinics.
Collapse
Affiliation(s)
- Y Liu
- Microbiology Resources, Institute of Applied Ecology, Chinese Academy of Science, Shenyang, China College of Resource and Environment, Graduate University of Chinese Academy of Sciences, Beijing, China Center for Drug Evaluation and Research, Tianjin Institute of Pharmaceutical Research, Tianjin, China
| | - M Xu
- Microbiology Resources, Institute of Applied Ecology, Chinese Academy of Science, Shenyang, China College of Resource and Environment, Graduate University of Chinese Academy of Sciences, Beijing, China Center for Drug Evaluation and Research, Tianjin Institute of Pharmaceutical Research, Tianjin, China
| | - Z Su
- Microbiology Resources, Institute of Applied Ecology, Chinese Academy of Science, Shenyang, China College of Resource and Environment, Graduate University of Chinese Academy of Sciences, Beijing, China Center for Drug Evaluation and Research, Tianjin Institute of Pharmaceutical Research, Tianjin, China
| | - Y Cai
- Microbiology Resources, Institute of Applied Ecology, Chinese Academy of Science, Shenyang, China College of Resource and Environment, Graduate University of Chinese Academy of Sciences, Beijing, China Center for Drug Evaluation and Research, Tianjin Institute of Pharmaceutical Research, Tianjin, China
| | - G Zhang
- Microbiology Resources, Institute of Applied Ecology, Chinese Academy of Science, Shenyang, China College of Resource and Environment, Graduate University of Chinese Academy of Sciences, Beijing, China Center for Drug Evaluation and Research, Tianjin Institute of Pharmaceutical Research, Tianjin, China
| | - H Zhang
- Microbiology Resources, Institute of Applied Ecology, Chinese Academy of Science, Shenyang, China College of Resource and Environment, Graduate University of Chinese Academy of Sciences, Beijing, China Center for Drug Evaluation and Research, Tianjin Institute of Pharmaceutical Research, Tianjin, China
| |
Collapse
|